Mostly extrapolated from adults. Most pediatric rows are Level C. Only sacubitril/valsartan (≥1 year), ivabradine (≥6 months), digoxin and furosemide carry a US label for heart failure in children; every other pediatric use is off-label.
| Class | Children (ISHLT 2025) | Adult HFrEF (AHA 2022) |
|---|---|---|
| IB LV systolic dysfunction, routinely | IA when ARNi is not feasible | |
| IIaC ACE inhibitor not tolerated | IA ACEi intolerant, ARNi not feasible | |
| IIaB symptomatic, in place of ACE inhibitor or ARB | IA NYHA II–III | |
| IIaC systemic LV systolic dysfunction | IA bisoprolol, carvedilol, metoprolol succinate | |
| IIaC symptomatic systemic LV dysfunction | IA eGFR >30, potassium <5.0 mEq/L | |
| IIbC symptomatic; not systematically studied | IA | |
| IIaB stable, heart-rate reduction wanted | IIaB-R sinus rhythm, HR ≥70 on beta-blocker | |
| IIbC symptoms, level e.g. 0.5–0.9 ng/ml | IIbB-R | |
| IC fluid retention, to euvolemia | IB-NR | |
| IIbC worsening despite optimized GDMT | IIbB-R | |
| IIaB iron deficiency | IIaB-R | |
| IIbC ACE inhibitor or ARB. Beta-blocker: caution (text, not graded) | Not covered here |
| Class | Recommendation | LOE |
|---|---|---|
| I | LV systolic dysfunction: ACE inhibitor routinely, unless specifically contraindicated | B |
| IIa | Systemic ventricular dysfunction, ACE inhibitor not tolerated: ARB is a reasonable alternative | C |
| Strength | Recommendation | Quality |
|---|---|---|
| Strong | Heart failure from primary heart-muscle disease of the systemic LV: ACE inhibitor indicated | Moderate |
CCS 2013 text: ARB therapy in children with heart failure is untested; it gives no graded ARB recommendation.
| Class | Recommendation | LOE |
|---|---|---|
| I | AHA: chronic HFrEF, ARNi not feasible: ACE inhibitor | A |
| I | AHA: ACE inhibitor intolerant (cough, angioedema), ARNi not feasible: ARB | A |
| III: Harm | AHA: ACE inhibitor with any history of angioedema | C-LD |
| I | ESC: ACE inhibitor to reduce heart failure hospitalization and death | A |
| I | ESC: ARB if an ACE inhibitor or ARNI is not tolerated (candesartan, losartan, valsartan) | B |
| Weight | Start | Second | Final |
|---|---|---|---|
| <40 kg (suspension or pellets) | 1.6 mg/kg | 2.3 mg/kg | 3.1 mg/kg |
| 40 to <50 kg | 24/26 mg | 49/51 mg | 72/78 mg |
| ≥50 kg | 49/51 mg | 72/78 mg | 97/103 mg |
| Weight | Start | Second | Final |
|---|---|---|---|
| 13 to <19 kg | 12/12 mg | 18/18 mg | 24/24 mg |
| 19 to <26 kg | 18/18 mg | 24/24 mg | 30/32 mg |
| 26 to <34 kg | 24/24 mg | 30/32 mg | 45/48 mg |
| 34 to <50 kg | 30/32 mg | 45/48 mg | 60/64 mg |
Pellets: open the capsule onto 1–2 teaspoons of soft food; do not chew or crush; never through a nasogastric, gastrostomy or other enteral tube (§2.5). Suspension 4 mg/mL from eight 49/51 mg tablets, kept up to 15 days, not refrigerated (§2.4).
| Class | Recommendation | LOE |
|---|---|---|
| IIa | ISHLT: symptomatic systemic LV systolic dysfunction: ARNI in place of an ACE inhibitor or ARB | B |
| I | AHA Adult HFrEF, NYHA II–III: ARNi | A |
| I | AHA Adult NYHA II–III tolerating an ACE inhibitor or ARB: replace it with ARNi | B-R |
| III: Harm | AHA Adult ARNi with an ACE inhibitor or within 36 hours of the last dose | B-R |
| III: Harm | AHA Adult ARNi with any history of angioedema | C-LD |
| I | ESC Adult sacubitril/valsartan as a replacement for an ACE inhibitor | B |
| Class | Recommendation | LOE |
|---|---|---|
| IIa | ISHLT: children with systemic LV systolic dysfunction As printed: the §4.4 text says beta-blockers “are recommended”; the graded row is Class IIa (“reasonable”). No evidence favours beta-1-selective over nonselective agents in young children. | C |
| I | AHA Adult bisoprolol, carvedilol or metoprolol succinate; not a class effect | A |
| I | ESC Adult stable HFrEF | A |
| Strength | Recommendation | Quality |
|---|---|---|
| Conditional | Moderate to severe systolic dysfunction of a systemic LV: carvedilol, metoprolol or bisoprolol might be started | Moderate |
| Class | Recommendation | LOE |
|---|---|---|
| IIa | ISHLT: children with symptomatic systemic LV dysfunction | C |
| I | AHA Adult NYHA II–IV, eGFR >30 and potassium <5.0 mEq/L | A |
| III: Harm | AHA Adult continuing when potassium cannot be kept <5.5 mEq/L | B-NR |
| I | ESC Adult MRA in HFrEF | A |
| Strength | Recommendation | Quality |
|---|---|---|
| Conditional | Chronic systolic heart failure with normal or mildly impaired renal function; watch renal function and potassium closely with an ACE inhibitor | Low |
| Class | Recommendation | LOE |
|---|---|---|
| IIb | ISHLT: children with symptomatic HFrEF | C |
| I | AHA Adult symptomatic chronic HFrEF, with or without type 2 diabetes | A |
| I | ESC Adult dapagliflozin or empagliflozin | A |
| Group | Start | Step | Maximum |
|---|---|---|---|
| <40 kg (oral solution 1 mg/mL) | 0.05 mg/kg | 0.05 mg/kg | 0.2 mg/kg (6 months to <1 year); 0.3 mg/kg (≥1 year); never above 7.5 mg |
| ≥40 kg (tablets) | 2.5 mg | 2.5 mg | 7.5 mg |
| Class | Recommendation | LOE |
|---|---|---|
| IIa | ISHLT: children with stable heart failure when heart-rate reduction is desirable | B |
| IIa | AHA Adult NYHA II–III, LVEF ≤35%, sinus rhythm, resting heart rate ≥70 on a maximally tolerated beta-blocker | B-R |
| IIa | ESC Adult LVEF ≤35%, sinus rhythm, resting heart rate ≥70 despite beta-blocker, ACE inhibitor (or ARNI) and MRA | B |
| IIa | ESC Adult the same, when a beta-blocker is not tolerated or contraindicated | C |
| Age | Maintenance, mcg/kg per dose | Total oral load, mcg/kg |
|---|---|---|
| Premature | 2.3–3.9 twice daily | 20–30 |
| Full-term | 3.8–5.6 twice daily | 25–35 |
| 1–24 months | 5.6–9.4 twice daily | 35–60 |
| 2–5 years | 4.7–6.6 twice daily | 30–45 |
| 5–10 years | 2.8–5.6 twice daily | 20–35 |
| Over 10 years | 3.0–4.5 once daily | 10–15 |
| Class | Recommendation | LOE |
|---|---|---|
| IIb | ISHLT: symptomatic HFrEF, for symptoms, at lower serum levels (e.g. 0.5–0.9 ng/ml) | C |
| IIb | AHA Adult symptomatic despite GDMT, to reduce hospitalization | B-R |
| IIb | ESC Adult sinus rhythm, symptomatic despite ACE inhibitor (or ARNI), beta-blocker and MRA | B |
| Class | Recommendation | LOE |
|---|---|---|
| I | ISHLT: fluid retention with ventricular dysfunction (stage C): diuretics to euvolemia | C |
| I | AHA Adult fluid retention: diuretics to relieve congestion | B-NR |
| I | AHA Adult add a thiazide only when moderate- or high-dose loop diuretics fail | B-NR |
| I | ESC Adult loop diuretic for congestion | C |
Biventricular circulation with a systemic LV: the LV recommendations are reasonable regardless of cause (ISHLT 2025 §6).
Chronic HFrEF in children: class by class, pediatric doses only where a label, guideline or trial prints one; adult grades and doses labelled